Life Blood. Issue 22. Index. t: medical website clinical guidelines products & services. Dear Life Blood Reader <---

Size: px
Start display at page:

Download "Life Blood. Issue 22. Index. t: medical website clinical guidelines products & services. Dear Life Blood Reader <---"

Transcription

1 <--- Life Blood clinical guidelines products & services feedback Dear Life Blood Reader Welcome to the 22nd Edition of Life Blood. The World Health Organisation EVD (Ebola Virus Disease) updates have not indicated spread to sub-saharan Africa. In light of this, WPBTS is continuing to rely on its deferral policy for donors who travel to malaria areas as this encompasses donations from individuals who have grown up in or travelled to an Ebola prevalent area. The National Guidelines for Issuing Blood to Viral Haemorrhagic Fever and Ebola Cases can be found in the previous edition of Life Blood. The 5th Edition of the Clinical Guidelines for the Use of Blood Products in South Africa has been released for distribution to hospital clinical staff. Its aim is to provide useful basic information about blood products available to clinicians in South Africa and brief guidelines for their optimum use. Other news featured in this edition is a comparison of platelet products, how to refer patients for therapeutic phlebotomy, the revised Cross-match Laboratory Request Form, and notice of the upcoming WPBTS 2015 Educational Seminar, the 33rd SA National Blood Transfusion Congress and the International Plasma Fractionation (IPFA) Workshop which are to be held in March, August and December 2015, respectively. Feel free to contact us should you have any queries. Regards Hayley Alie Marketing Officer Dr Caroline Hilton Transfusion Medical Specialist Index Clinical Guidelines for the Use of Blood Products in SA, 5th Edition Page 2 A Comparison Between Pooled and Single Donor Platelets Page 2 Revised Cross-match Laboratory Request Form Page 5 Your Questions Answered Page 5 Events Diary Page 6 1

2 <--- Life Blood Clinical Guidelines for the Use of Blood Products in South Africa, 5th Edition In January 2015, the 5th Edition of the Clinical Guidelines for the Use of Blood Products in South Africa, was released for distribution to hospital clinical staff. The Guidelines are jointly published by the Western Province Blood Transfusion Service (WPBTS) and the South African National Blood Service (SANBS). Its aim is to provide useful basic information about blood products available to clinicians in South Africa and brief guidelines for their optimum use. I wish to take this opportunity to acknowledge Adcock Ingram Critical Care as the proud sponsors of the booklet and convey our heartfelt thanks and gratitude to them for their support. Notable changes in the 5th Edition are the inclusion of two new chapters which cover the management of massive blood loss, and HIV/AIDS and blood transfusion. A new section about transfusion-related immunomodulation, has also been added. It is our aim that one copy of the booklet be kept in every ward using blood products preferably at the nurse s station. The PDF version of the Guidelines is available on the WPBTS website. Please note that a few booklets may have missing and/or duplicated pages. Feel free to contact the WPBTS Marketing Officer should you require a new or replacement copy. Hayley Alie, WPBTS Marketing Officer Telephone , Cellphone , Fax , marketing@wpbts.org.za A Comparison Between Pooled and Single Donor Platelets Clinical Indications for Platelet Transfusions The indications for platelet usage are summarised below. Refer to the Clinical Guidelines for the Use of Blood Products in SA, 5th Edition, Chapter 4 for more information. Platelet transfusions are indicated for the prevention and treatment of bleeding in patients with thrombocytopenia or platelet function defects. The cause of the thrombocytopenia should be established before a decision is made to transfuse platelets since not all causes of thrombocytopenia are responsive to platelet transfusion and may even be contraindicated in some conditions. Bone marrow failure: Therapeutic platelet transfusions, prophylactic platelet transfusions, acute leukaemia, haemopoietic stem cell transplantation, chronic stable thrombocytopenia Prophylaxis for surgery: Lumbar puncture, epidural anaesthesia, gastroscopy and biopsy, insertion of indwelling lines, transbronchial biopsy, liver biopsy, laparotomy or similar procedures Massive transfusion Disseminated intravascular coagulation (DIC) Cardiopulmonary bypass (CPB) Liver transplantation Immune thrombocytopenias: Autoimmune thrombocytopenia, neonatal alloimmune thrombocytopenia (NAIT), post transfusion purpura Platelet transfusions are contraindicated in autoimmune thrombocytopenia, Thrombotic Thrombocytopenic Purpura (TTP) and in Heparin Induced Thrombocytopenia (HIT). <--- 2

3 Life Blood Collection and Processing Methods Pooled platelets are obtained from 5 or more individual whole blood donations, which are bled within 12 minutes, from donors who have not taken aspirin or anti-inflammatories within the past 7 days. After collection, the whole blood is centrifuged and the buffy coat layer, which is rich in platelets and leucocytes, is separated. The individual buffy coats are pooled into one bag and the plasma from one of the donations in the pool is added up to a set volume. The pool is then centrifuged and the platelets and plasma are removed by separation. Leucocyte reduced pooled platelets are produced on request, by filtering the final pooled platelet product. Single donor platelets are harvested from individual platelet donations, from donors who have not taken aspirin or anti-inflammatories within the past 7 days, using the Haemonetics MC3P and the Cobe Trima machines, at our Apheresis Platelet Donation Unit. This is situated at our headquarters in Pinelands, Cape Town. The procedure takes about 90 minutes. The platelets are collected by the donor blood passing through a continuously spinning centrifuge, where the platelets are removed and collected, after which the remaining plasma and red cells are returned to the donor. The process undergoes simultaneous leucodepletion. Infant and paediatric single donor platelets are produced by splitting the individual donation into smaller volumes according to the platelet count and volume of the original product. These platelets are leucocyte depleted. < < 3

4 <--- Life Blood Product Array Pooled Platelet Platelet Count 2.4 x Volume ± 300 ml Leucocyte Reduced Pooled Platelet Adult Single Donor Apheresis Mega-Platelet Platelet Count 2.4 x Volume 250 ml ± 50 ml Paediatric Single Donor Apheresis Mega-Platelet Platelet Count Leucocyte Count Volume 2.4 x x 10 6 /unit 250 ± 50 ml Platelet Count 1.5 x Volume 150 ml ± 50 ml Infant Single Donor Apheresis Mega-Platelet Platelet Count Volume 5.5 x ml ± 10 ml The Benefits of Single Donor Platelets The complete platelet dose is derived from a single donor. Reduced donor exposure for the patient. Reduced risk of alloimmunisation to HLA antigens. Product is integrally leucocyte depleted. Minimal product intervention. Ordering Platelets Pooled platelets are processed daily (weekdays) and stocks are distributed to the Blood Banks, ensuring that they are readily available on request. Single donor platelets are collected from the donor after the clinician has requested the platelets from the Blood Bank or our Apheresis Platelet Donation Unit. These platelet requests should be ordered by 12h00 on weekdays to ensure that the fully tested platelet product is available the same evening. A limited emergency supply is kept for after-hours usage on weekends and public holidays. The clinician should clearly indicate whether the platelet product should be HLA-matched, gamma-irradiated, leucocyte reduced, is for designated donation or autologous transfusion. Price Comparison Because platelet products have a short expiry i.e. 5 days, and incur high collection/processing costs, the Blood Service must carefully manage the stocks in order to prevent wastage. Single donor platelet products cost 10% more than their comparative product i.e. leucocyte reduced pooled platelets. A separate fee is charged for gamma-irradiation of products and designated/ autologous platelet collections and the cost of the platelet search which is performed by the SA Bone Marrow Registry. <--- 4

5 <--- Life Blood Revised Cross-match Laboratory Request Form As of October 2014, the revised WPBTS Cross-match Laboratory Request Form has been phased in. It is imperative that the form is completed accurately and that all sections are filled in. The top five rules for completing the Request Form are as follows. 1. The patient s particulars must be filled in accurately. 2. Every sheet must contain all the patient s particulars. When using the patient sticker, please check that there are no other patient stickers on the form. 3. The requesting doctor s name must be filled in. 4. The phlebotomist s name and signature, as well as the date and time that the specimen was taken, must be completed. 5. The hospital name and ward must be provided. The Cross-match Laboratory Request Form is available from your nearest Blood Bank. Your Questions Answered How do I refer patients with elevated iron levels or polycythaemia to donate blood? This is a reminder to clinicians that all patients who are required to donate blood for medical reasons should be formally enrolled in the WPBTS therapeutic phlebotomy programme. It is not appropriate to advise your patient to donate blood without informing WPBTS, as we need to ascertain whether their blood is safe for use in our general supply. It is not suitable to use blood from patients with elevated iron levels secondary to malignancy, autoimmune disease or undiagnosed inflammatory conditions. Similarly, the blood from patients with polycythaemia vera or high affinity haemoglobin abnormalities should not be given to others. If you would like to refer a patient to our service for venesections for a medical reason, please contact the therapeutic clinic at phlebotomy@wpbts.org.za or (021) /48. You will be required to complete a referral form and supply necessary blood results. If you suspect your patient has hereditary haemochromatosis, genetic testing should be performed. Blood from haemochromatosis patients can be used to make blood products, provided that there is no significant liver function enzyme derangement. JAK-2 testing results should also be supplied if the patient is diagnosed with polycythaemia vera. The causes of secondary iron overload or polycythaemia must please be stipulated on the referral form in order to expedite enrolment of the patient. The referral will be reviewed by the WPBTS <--- 5

6 Life Blood doctor and if accepted, the patient will be contacted to book their first visit. Please note that people with severe comorbid disease will not be allowed to donate at our service as there is not adequate medical support for unstable patients, so these people should be venesected in hospitals or doctor s rooms. The first blood donation will take place at our therapeutic phlebotomy clinic situated at our head office (Pinelands) or regional offices (Paarl, Worcester, George). The patient will be charged for the first donation. If the patient copes well with the donation and there are no problematic co-morbid diseases (eg. insulin dependent diabetes, significant cardiac disease), they can donate at regular clinics thereafter. Subsequent donations are free of charge provided the patient s blood can be used in the general blood supply. If their blood cannot be used due to the underlying condition or use of contraindicated medications (eg. Warfarin), they will be charged for each donation. Clinicians who refer polycythaemic patients are provided with full blood count results at every donation in order to guide the patient s bleeding schedule. It is advised that the ferritin level is checked after every sixth donation for hyperferritinaemic patients in order to determine how often they should be venesected. For further information or queries, please contact Dr Caroline Hilton (caroline@wpbts.org.za) or the therapeutic clinic team (phlebotomy@wpbts.org.za). Therapeutic Phlebotomy Clinic Particulars Head Office Wednesdays (08h00-14h30) Tel: /48, Fax: Old Mill Road, Pinelands, 7405, Cape Town Regional Offices Paarl Thursdays (10h00 19h30) Tel: Main Road, Paarl Worcester Tuesdays (09h00 19h45) Tel: Napier Street, Worcester George Wednesdays (12h00 19h00) & Fridays (10h00 15h00) Tel: Medical Centre, Courtenay Street, George Events Diary You are warmly invited to join us for the following events where we ll keep you up to date with the latest developments in blood transfusion. Please diarise and register now! WPBTS 2015 Educational Seminar Theme: Blood Transfusion Where: WPBTS Auditorium, Old Mill Road, Pinelands, 7405 When: Saturday, the 28th of March 2015 Time: 08h00 until 13h00 Cost: Free of charge Click here for the invitation flyer <--- 6 <---

7 Life Blood 33rd SA National Blood Transfusion Congress Theme: Conserving Precious Resources from Donor to Patient Where: Champagne Sports Resort in the Drakensberg When: 24th until the 27th of August 2015 Please feel free to visit the Congress Website ( for more information. On behalf of the International Plasma Fractionation Association (IPFA), I am pleased to bring to your attention their workshop on Improving Access to Plasma and Plasma Products in the Southern African Region, which is to be held on 1-2 December 2015 in Stellenbosch (Cape Town), South Africa. This Workshop reflects IPFA s priority goal and actions to help increase the global supply of plasma for fractionation and will build on IPFA s traditions of open and inclusive discussions between all stakeholders who may have an interest in and/or responsibility for meeting the increasing need for plasma derivatives in the Southern African Region. International Plasma Fractionation Association (IPFA) Workshop Theme: Improving Access to Plasma and Plasma Products in the Southern African Region Where: Spier Hotel and Conference Centre, Stellenbosch When: 1st until the 2nd of December 2015 Please feel free to visit the IPFA Congress Website ( for more information. Click here for the announcement flyer <--- 7

8

9

10

Aim. To provide basic knowledge on the processing, testing and issue of blood donations by NHSBT

Aim. To provide basic knowledge on the processing, testing and issue of blood donations by NHSBT From Donor To Door Aim To provide basic knowledge on the processing, testing and issue of blood donations by NHSBT At the end of this session you will be aware of: The stages of processing, testing and

More information

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD Platelet Refractoriness: The Basics Martin H. Bluth, MD, PhD Complete Toxicology Laboratories, LLC Objectives Define platelet refractoriness and associated conditions that may cause platelet refractoriness.

More information

Blood Product Utilization

Blood Product Utilization Who gets what & when Why not to give blood? Volume Expander For specific number (except as related to procedures) To patients with religious objections to blood transfusions Blood given only when necessary

More information

Therapeutic Apheresis Services. Annual Review 2015/16

Therapeutic Apheresis Services. Annual Review 2015/16 Therapeutic Apheresis Services Annual Review 2015/16 1 OVERVIEW NHS Blood and Transplant (NHSBT) is a major provider of Therapeutic Apheresis Services (TAS) in the NHS. At the end of each financial year,

More information

BLOOD ADMINISTRATION PROTOCOL

BLOOD ADMINISTRATION PROTOCOL BLOOD ADMINISTRATION PROTOCOL Document ID: HPBBADM0302 Version: 5.0 Ratified by: Date ratified: February 2011 Name of originator/author: Name of responsible committee/individual: Date issued: February

More information

Blood Component Preparation and Therapeutic Utilization

Blood Component Preparation and Therapeutic Utilization Blood Component Preparation and Therapeutic Utilization Prof. A. Pourazar Immunohematologist and Transfusion medicine School of Medicine, Isfahan University Of Medical Science IRAN Red Blood cells, Platelets

More information

REGIONAL AUDIT OF PLASMA PRODUCTS 2016

REGIONAL AUDIT OF PLASMA PRODUCTS 2016 REGIONAL AUDIT OF PLASMA PRODUCTS 2016 Background: In 2010, the East of England RTC carried out an audit of the use of Fresh Frozen Plasma (FFP) in adult patients. With the introductions of trauma networks

More information

PLATELET GUIDANCE DOCUMENT

PLATELET GUIDANCE DOCUMENT Government of Newfoundland and Labrador Department of Health and Community Services Provincial Blood Coordinating Program PLATELET GUIDANCE DOCUMENT Office of Administrative Responsibility Director, Regional

More information

Home truths... the clinical use of components in the UK. Jonathan Wallis. Platelets, FFP, Cryoprecipitate

Home truths... the clinical use of components in the UK. Jonathan Wallis. Platelets, FFP, Cryoprecipitate Home truths... the clinical use of components in the UK Platelets, FFP, Cryoprecipitate Jonathan Wallis Mar-01 Mar-02 Mar-03 Mar-04 Mar-05 Mar-06 Mar-07 Mar-08 Mar-09 Mar-10 Mar-11 Mar-12 E&N.Wales Platelet

More information

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work. Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion

More information

Manejo de la transfusión de plaquetas. Ileana López-Plaza, MD

Manejo de la transfusión de plaquetas. Ileana López-Plaza, MD Manejo de la transfusión de plaquetas Ileana López-Plaza, MD Thrombocytopenia Common in ICU setting 25-38% with< 100,000/µL 2-3 % with < 10,000/µL Common etiologies Drug-induced: heparin, antibiotics,

More information

CURRENT COURSE OFFERINGS

CURRENT COURSE OFFERINGS The American Red Cross offers regular educational opportunities as a convenient way for healthcare providers to receive relevant blood banking and transfusion medicine information. The bi-monthly sessions,

More information

Category Storage Shelf Life Additional Criteria

Category Storage Shelf Life Additional Criteria CE Update [blood banking/transfusion medicine] Blood Components for Hemostasis Jun Teruya, MD, DSc, and Glenn Ramsey, MD From the Department of Pathology, Northwestern University Medical School, Chicago.

More information

Blood transfusion in special situations and poly-trauma. Dr Marina Karakantza Consultant Haematologist in Transfusion Medicine, LTHT

Blood transfusion in special situations and poly-trauma. Dr Marina Karakantza Consultant Haematologist in Transfusion Medicine, LTHT Blood transfusion in special situations and poly-trauma Dr Marina Karakantza Consultant Haematologist in Transfusion Medicine, LTHT Uncontrolled bleeding is a major preventable cause of death in trauma

More information

Guideline for Theraputic Plasma Exchange

Guideline for Theraputic Plasma Exchange Guideline for Theraputic Plasma Exchange Therapeutic plasma exchange (TPE) removes large-molecular-weight substances such as harmful antibodies from the plasma. It is usually carried out using an automated

More information

The clinical utility of IPF in thrombocytopenia

The clinical utility of IPF in thrombocytopenia The clinical utility of IPF in thrombocytopenia Platelets platelets Platelets are the smallest blood cells which are released by cytoplasmic blebbing of megakaryocytes with an average size of 2um. Normal

More information

Paul Ashford Executive Director ICCBBA

Paul Ashford Executive Director ICCBBA Introduction to ISBT 128 Paul Ashford Executive Director ICCBBA ICCBBA ICCBBA enhances safety for patients by managing the ISBT 128 international information standard for use in transfusion and transplantation.

More information

Blood Component Therapy and Apheresis

Blood Component Therapy and Apheresis Blood Component Therapy and Apheresis Dr. Debasish Gupta Program Director, CHF International TRANSFUSION THERAPY Used primarily to treat two conditions Inadequate oxygen carrying capacity because of anemia

More information

Alberta Health Services - Edmonton Zone Massive Hemorrhage Protocol

Alberta Health Services - Edmonton Zone Massive Hemorrhage Protocol This document applies to all Covenant and AHS sites. Client Resource 23: Alberta Health Services - Edmonton Zone Regional Laboratory Services This document is applicable at site(s): GNH MIS RAH SGH UAH

More information

Producing Blood Components from donated Whole blood, or The art of the Impossible? Ian Symonds, Manufacturing Manager NHSBT Colindale

Producing Blood Components from donated Whole blood, or The art of the Impossible? Ian Symonds, Manufacturing Manager NHSBT Colindale Producing Blood Components from donated Whole blood, or The art of the Impossible? Ian Symonds, Manufacturing Manager NHSBT Colindale Where does the blood come from & where does it go? Nationally we have

More information

NHSBT Portfolio of Blood Components and Guidance for their Clinical Use. Summary of Significant Changes. Purpose. Definitions. Applicable Documents

NHSBT Portfolio of Blood Components and Guidance for their Clinical Use. Summary of Significant Changes. Purpose. Definitions. Applicable Documents This Specification replaces SPN223/7 Copy Number Effective: 21/12/16 Summary of Significant Changes Introduction of HEV testing, and Pooled Platelets in Plasma/Additive mixture Amendment to interruption

More information

Transfusion effect of random donor platelet and single donor platelet in thrombocytopenic patients at tertiary care hospital of South Gujarat

Transfusion effect of random donor platelet and single donor platelet in thrombocytopenic patients at tertiary care hospital of South Gujarat International Journal of Research in Medical Sciences Unagar CA et al. Int J Res Med Sci. 2017 Jul;5(7):3033-3037 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20172983

More information

CHANGE IN PLATELET USAGE

CHANGE IN PLATELET USAGE Paula Bolton-Maggs CHANGE IN PLATELET USAGE 2007-2013 275 270 265 260 255 250 245 240 235 230 225 220 215 210 205 200 Moving Annual Total of Platelet Issues to Hospitals - 000s 4.1 % 2.3 % -0.5 % -1.8

More information

Platelet transfusion therapy. Orieji Illoh, M.D. January 23, 2007

Platelet transfusion therapy. Orieji Illoh, M.D. January 23, 2007 Platelet transfusion therapy Orieji Illoh, M.D. January 23, 2007 The Eighteenth Century Transfusions were done only sporadically, and were generally animal to human. Transfusion was generally thought of

More information

Looking after a Finite Resource. Adrian Ebbs Transfusion Laboratory Manager Queen Elizabeth Hospital King s Lynn

Looking after a Finite Resource. Adrian Ebbs Transfusion Laboratory Manager Queen Elizabeth Hospital King s Lynn Looking after a Finite Resource Adrian Ebbs Transfusion Laboratory Manager Queen Elizabeth Hospital King s Lynn Supply Chain Cold Chain Red Cells Platelets Blood Stocks Management Scheme Aim of Stock Management

More information

ANEMIA. Oral iron. IV iron gluconate (order set #233)

ANEMIA. Oral iron. IV iron gluconate (order set #233) PREVENTION ANEMIA Oral iron IV iron gluconate (order set #233) TRANSEXAMIC ACID Efficacy of IV TXA in Reducing Blood Loss After Elective C-section: Prospective, Randomized, Double-blind, Placebo Controlled

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Garban F, Guyard A, Labussière H, et al; Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group. Comparison of the hemostatic

More information

Ebola Convalescent Plasma: Considerations for future outbreaks

Ebola Convalescent Plasma: Considerations for future outbreaks Ebola Convalescent Plasma: Considerations for future outbreaks Based on EVD-001 and -002 Monrovia; Liberia Nov 2014-Jan 2015 For IPFA s Workshop on Improving Access to Plasma and Plasma Products in the

More information

Customer Satisfaction Survey Platelet Immunology Laboratory May 2018

Customer Satisfaction Survey Platelet Immunology Laboratory May 2018 A specialty segment of physicians was targeted to receive this survey. The target group consisted of physicians who have ordered testing to investigate patients suspected of being refractory to platelets.

More information

Massive Haemorrhage J Davies B Ferguson

Massive Haemorrhage J Davies B Ferguson Massive Haemorrhage J Davies B Ferguson What is Massive Haemorrhage (MH)? Difficult to apply rules as to how much blood loss defines a major haemorrhage. Easier to define how the patient s condition is

More information

REGIONAL LIAISON COMMITTEE, Vancouver

REGIONAL LIAISON COMMITTEE, Vancouver REGIONAL LIAISON COMMITTEE, Vancouver SUMMARY NOTES of the meeting of the Canadian Blood Services Regional Liaison Committee held in Thursday, January 25, 2007 at 5:00 p.m. PRESENT: OBSERVING REGRETS:

More information

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects. Heparin Induced Eric Kraut, MD Professor of Internal Medicine The Ohio State University Medical Center Heparin Induced Heparin induced thrombocytopenia occurs in up to 5 % of patients receiving unfractionated

More information

Irish Blood Transfusion Service Seirbhís Fuilaistriúcháin na héireann

Irish Blood Transfusion Service Seirbhís Fuilaistriúcháin na héireann Document Detail Irish Blood Transfusion Service Seirbhís Fuilaistriúcháin na héireann Type: Document No.: Title: PMF IBTS SPEC IBTS/PMF/SPEC/0201[2] PRODUCT MASTER FILE - GENERAL REQUIREMENTS Owner: 1066

More information

iccnet CHSA Clinical Protocol - HEPARIN

iccnet CHSA Clinical Protocol - HEPARIN Name: iccnet CHSA Clinical Protocol - HEPARIN This clinical guideline or clinical protocol is based on a review of best practice evidence and expert opinion. It is intended to guide practice and does not

More information

Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.

Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D. Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin

More information

Donor Informed Consent to Participate in Research

Donor Informed Consent to Participate in Research Donor Informed Consent to Participate in Research This is a consent form for a research study. This clinical trial is a research study to determine better treatment for patients with Multiple Myeloma (MM).

More information

Vein-to-Vein: Creating New Products to Optimize Patient Outcomes

Vein-to-Vein: Creating New Products to Optimize Patient Outcomes Vein-to-Vein: Creating New Products to Optimize Patient Outcomes BETH H. SHAZ, MD CHIEF MEDICAL AND SCIENTIFIC OFFICER EXECUTIVE VICE PRESIDENT NEW YORK BLOOD CENTER N Y B C. O R G S A V E A L I F E N

More information

ThromboLUX for determining platelet quality

ThromboLUX for determining platelet quality Updating information provided by the company October 2012 Horizon Scanning Centre October 2011 ThromboLUX for determining platelet quality SUMMARY Lay summary click here This briefing is based on information

More information

Stem Cells and Multiple Myeloma

Stem Cells and Multiple Myeloma Stem Cells and Multiple Myeloma What is Multiple Myeloma Multiple Myeloma is a cancer of your plasma cells, a type of white blood cell present in your bone marrow Plasma cells normally make proteins called

More information

Consulted With; Post/Committee/Group Date Haematology Dr Shereen Elshazly (Lead for Anticoagulation) January 2016 Department of Anaesthesia

Consulted With; Post/Committee/Group Date Haematology Dr Shereen Elshazly (Lead for Anticoagulation) January 2016 Department of Anaesthesia Peri-procedural anticoagulation in Adult patients taking Warfarin and novel oral anti-coagulants (NOACS) Clinical Guideline Register No: 16005 Status: Public Developed in response to: Contributes to CQC

More information

SYLLABUS FOR M.D. IMMUNO HAEMATOLOGY & TRANSFUSION MEDICINE SYLLABUS

SYLLABUS FOR M.D. IMMUNO HAEMATOLOGY & TRANSFUSION MEDICINE SYLLABUS SYLLABUS FOR M.D. IMMUNO HAEMATOLOGY & TRANSFUSION MEDICINE 17. Concurrent study of Post Graduate Diploma A candidate admitted to undergo a Three year M.D. Transfusion Medicine Post Graduate Degree Clinical

More information

Managing platelet refractory patients: case studies. Presented by Paul F. Lindholm, M.D.

Managing platelet refractory patients: case studies. Presented by Paul F. Lindholm, M.D. Managing platelet refractory patients: case studies Presented by Paul F. Lindholm, M.D. Platelet transfusion Thrombocytopenia/transfusion goals Prophylactic >10K/mL to prevent serious bleeding (prophylactic)

More information

4/22/2015. Platelet antibody screen and crossmatch. HLA antibody testing methods. Matched platelet timeline. Lymphocytotoxicity. Luminex technology

4/22/2015. Platelet antibody screen and crossmatch. HLA antibody testing methods. Matched platelet timeline. Lymphocytotoxicity. Luminex technology Managing platelet refractory patients: case studies Presented by Paul F. Lindholm, M.D. Platelet transfusion Thrombocytopenia/transfusion goals Prophylactic >10K/mL to prevent serious bleeding (prophylactic)

More information

South African National Blood Service Business Model and Challenges Presentation to Portfolio Committee on Health 14 OCTOBER 2009

South African National Blood Service Business Model and Challenges Presentation to Portfolio Committee on Health 14 OCTOBER 2009 South African National Blood Service Business Model and Challenges Presentation to Portfolio Committee on Health 14 OCTOBER 2009 Overview of SANBS SANBS is a section 21 company, not for gain. Provides

More information

Massive Haemorrhage P Donnelly B Ferguson

Massive Haemorrhage P Donnelly B Ferguson Massive Haemorrhage P Donnelly B Ferguson What is Massive Haemorrhage (MH)? Difficult to apply rules as to how much blood loss defines a major haemorrhage. Easier to define how the patient s condition

More information

Coordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin

Coordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin Coordinated Primary Options Service DVT Management Plan Management options using Dabigatran or Warfarin Name NHI DOB Ethnicity Gender Address Contact Information Mobile Home Treatment commenced date *CPO

More information

CIR Blood Resource OVERVIEW Use of healthy donor human blood New ethics protocol from 2016

CIR Blood Resource OVERVIEW Use of healthy donor human blood New ethics protocol from 2016 University of Edinburgh / MRC Centre for Inflammation Research November 2015 CIR Blood Resource OVERVIEW Use of healthy donor human blood New ethics protocol from 2016 KEY CHANGES FROM 2016 New ethics

More information

ASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS

ASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS ASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS Guideline Title Assessing the Efficacy and Safety of Normal Intravenous Immunoglobulin Products

More information

Debbie Asher Chief BMS, Norfolk and Norwich University Hospital SHOT Working Expert Group

Debbie Asher Chief BMS, Norfolk and Norwich University Hospital SHOT Working Expert Group Debbie Asher Chief BMS, Norfolk and Norwich University Hospital SHOT Working Expert Group Improve patient safety through the improvement of standards of hospital transfusion practice Aid in the production

More information

Microparticles in platelet concentrates are a key indicator of the level of platelet activation. This is a topic that is critically important to

Microparticles in platelet concentrates are a key indicator of the level of platelet activation. This is a topic that is critically important to Microparticles in platelet concentrates are a key indicator of the level of platelet activation. This is a topic that is critically important to understand in more detail. Based on the literature between

More information

The King s Liver Research Tissue Bank

The King s Liver Research Tissue Bank Liver, Renal & Surgery The King s Liver Research Tissue Bank Information for patients This leaflet explains why we have asked you to donate to our Tissue Bank and how we use donated samples. If you have

More information

The Cell and Gene Therapy Catapult UK clinical trials database

The Cell and Gene Therapy Catapult UK clinical trials database The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)

More information

Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108

Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108 A Accuracy, 6, 7, 15, 46, 52, 53, 61, 75, 100, 143, 144, 149, 166, 176, 178 Acquired coagulation disorders, 111 115 Acquired platelet disorders, 99 108 ACT. See Activated clotting time (ACT) Activated

More information

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3. Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.1; 14 Apr 2016) VI.2 VI.2.1 Elements for a Public Summary Overview of

More information

Cryoprecipitate audit within six centres in New Zealand.

Cryoprecipitate audit within six centres in New Zealand. Cryoprecipitate audit within six centres in New Zealand. Final Report Audit data collated by: Rachel Donegan : Auckland Rebecca Charman: Manukau Christopher Corkery : Hamilton Catherine Hammond :Wellington

More information

AIMS FELLOWSHIP CURRICULUM GENERAL/CORE LABORATORY IV

AIMS FELLOWSHIP CURRICULUM GENERAL/CORE LABORATORY IV AIMS FELLOWSHIP CURRICULUM GENERAL/CORE LABORATORY IV Module Code: GENERAL IV (Compulsory Module) Module Title: Haematology Module Convenor: Mr David Condie, B. App.Sci (QUT), FAIMS,MASM, MBA Senior Scientist

More information

New Drug Therapies for ITP

New Drug Therapies for ITP Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/new-drug-therapies-for-itp/3710/

More information

Myeloma XII (ACCoRd) Myeloma Infosheet Series. Clinical trials and novel drugs Infoline:

Myeloma XII (ACCoRd) Myeloma Infosheet Series. Clinical trials and novel drugs Infoline: Myeloma XII (ACCoRd) This Infosheet provides information about what the Myeloma XII clinical trial is, why it is taking place and what is involved if patients decide to take part in the trial. This Infosheet

More information

ISBT128 Standards for Blood and Blood Components: How it Translates to Patient Safety

ISBT128 Standards for Blood and Blood Components: How it Translates to Patient Safety ISBT128 Standards for Blood and Blood Components: How it Translates to Patient Safety Diana Teo Blood Services Group Health Sciences Authority Singapore 11/12/2010 1 All Rights Reserved 2008 Health Sciences

More information

ABO Typing Discrepancies

ABO Typing Discrepancies Jayme Heimonen MT(ASCP)SBB Blood Bank Technical Specialist Borgess Medical Center Kalamazoo, MI ASCLS-Michigan 2016 1 Expected reactions are missing 4+ 0 4+ 0 0 0 0 0 4+ 0 0 3+ 2 Unexpected reactions are

More information

STANDARD BLOOD PRODUCTS AND SERVICES

STANDARD BLOOD PRODUCTS AND SERVICES STANDARD BLOOD PRODUCTS AND SERVICES Policy NHP reimburses contracted providers for the medically necessary administration (transfusion) of blood and standard blood products. Prerequisites Authorization,

More information

Against this background, the use of multiple doses, principally double, continues. The purpose of this audit was to:-

Against this background, the use of multiple doses, principally double, continues. The purpose of this audit was to:- London Regional Transfusion Committee Audit of Multiple Dose Platelet Transfusion Requests across the London Regional Transfusion Committee region during a one week period in December 2014. Rachel Moss,

More information

HAEMOVIGILANCE. Ms. Emma O Riordan.

HAEMOVIGILANCE. Ms. Emma O Riordan. HAEMOVIGILANCE a set of surveillance procedures covering the whole transfusion chain from the collection of blood and its components to the follow-up of its recipients, intended to collect and assess information

More information

Section 8. To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS)

Section 8. To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS) Section 8 Practicalities Blood Collection Aim To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS) Learning Outcomes To identify the equipment used for

More information

Partners for Life with Canadian Blood Services

Partners for Life with Canadian Blood Services Partners for Life with Canadian Blood Services What is Partners for Life? Partners for Life program is a nationwide program that is designed for corporate and community organizations. When your company

More information

Anti- THrombosis with Enoxaparin in intubated Adolescents

Anti- THrombosis with Enoxaparin in intubated Adolescents Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question

More information

Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis

Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis 1 Nadanotes.com 2 Nadanotes.com 3 Nadanotes.com Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis Clotting

More information

To enable the learner to develop an understanding of the various stages of Intraoperative Cell Salvage (ICS)

To enable the learner to develop an understanding of the various stages of Intraoperative Cell Salvage (ICS) Section 6 Principles of Intraoperative Cell Salvage Aim To enable the learner to develop an understanding of the various stages of Intraoperative Cell Salvage (ICS) Learning Outcomes Identify the three

More information

The Cell and Gene Therapy Catapult UK clinical trials database

The Cell and Gene Therapy Catapult UK clinical trials database The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)

More information

Clinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test.

Clinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test. NHS GREATER GLASGOW AND CLYDE BOWEL SCREENING PROGRAMME Clinical Policy Guidelines Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test. Date to

More information

Performance by business line

Performance by business line Performance by business line Transfusable Products Transfusable Products includes all activities related to the supply of fresh blood products to hospitals, including donor recruitment, collection of whole

More information

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications Thromboelastography (TEG): Basics & Clinical Applications Paula J. Santrach MD Associate Professor, Laboratory Medicine Mayo Clinic Rochester, MN Disclosures Relevant financial relationships NONE Off label

More information

INTERNATIONAL SPECIALIST IN BLOOD BANKING WORK EXPERIENCE DOCUMENTATION FORM (Routes 2 & 3)

INTERNATIONAL SPECIALIST IN BLOOD BANKING WORK EXPERIENCE DOCUMENTATION FORM (Routes 2 & 3) PART I (TO BE COMPLETED BY APPLICANT) Applicant s Name Address Email Address PART II (MUST BE COMPLETED AND SIGNED BY LABORATORY MANAGEMENT* OR EMPLOYER IN ORDER TO BE ACCEPTABLE) SUBJECT: VERIFICATION

More information

If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom

If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom Heparin Discovered 1916, commercial available 1935 Heparin Is there an alternative, not really

More information

INTERNATIONAL SPECIALIST IN BLOOD BANKING WORK EXPERIENCE DOCUMENTATION FORM (Routes 2 & 3)

INTERNATIONAL SPECIALIST IN BLOOD BANKING WORK EXPERIENCE DOCUMENTATION FORM (Routes 2 & 3) PART I (TO BE COMPLETED BY APPLICANT) Applicant s Name Address Email Address PART II (MUST BE COMPLETED AND SIGNED BY LABORATORY MANAGEMENT* OR EMPLOYER IN ORDER TO BE ACCEPTABLE) SUBJECT: VERIFICATION

More information

What does it mean for general practice?

What does it mean for general practice? The New Zealand Laboratory Schedule and Test Guidelines: What does it mean for general practice? 2 November 2013 best tests A new schedule for laboratory testing in New Zealand In October, 2013, a new

More information

Immunotherapy in myeloma

Immunotherapy in myeloma Immunotherapy in myeloma Horizons Infosheet Clinical trials and novel drugs This Horizons Infosheet provides information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons

More information

PROTOCOL FOR A RESEARCH SAMPLE REPOSITORY FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, OTHER CELLULAR THERAPIES AND MARROW TOXIC INJURIES

PROTOCOL FOR A RESEARCH SAMPLE REPOSITORY FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, OTHER CELLULAR THERAPIES AND MARROW TOXIC INJURIES Center for International Blood and Marrow Transplant Research PROTOCOL FOR A RESEARCH SAMPLE REPOSITORY FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, OTHER CELLULAR THERAPIES AND MARROW TOXIC

More information

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Summer Syed (local PI) Keyvan Karkouti Deputy Anesthesiologist-in-Chief, Toronto General Hospital, University Health

More information

SPECIALIST IN BLOOD BANKING WORK EXPERIENCE DOCUMENTATION FORM (Routes 2, 3, & 4)

SPECIALIST IN BLOOD BANKING WORK EXPERIENCE DOCUMENTATION FORM (Routes 2, 3, & 4) PART I (TO BE COMPLETED BY APPLICANT) Applicant s Name Last Four Digits of Applicant s Social Security # Address Email Address Daytime Telephone Number PART II (MUST BE COMPLETED AND SIGNED BY THE IMMEDIATE

More information

TITLE: Extended Storage of Pathogen-Reduced Platelet Concentrates (PRECON) Seattle, WA 98104

TITLE: Extended Storage of Pathogen-Reduced Platelet Concentrates (PRECON) Seattle, WA 98104 AWARD NUMBER: W81XWH-13-2-0089 TITLE: Extended Storage of Pathogen-Reduced Platelet Concentrates (PRECON) PRINCIPAL INVESTIGATOR: Sherrill J. Slichter, MD CONTRACTING ORGANIZATION: Puget Sound Blood Center

More information

Instructions for Hematopoietic Stem Cell Transplant (HSCT) Infusion Form 2006

Instructions for Hematopoietic Stem Cell Transplant (HSCT) Infusion Form 2006 Instructions for Hematopoietic Stem Cell Transplant (HSCT) Infusion Form 2006 E-mail comments regarding the content of the CIBMTR Forms Instruction Manual to: CIBMTRFormsManualComments@nmdp.org. Comments

More information

REQUIREMENTS OF PLASMA COLLECTION FOR PDMPs IPFA, YOGYAKARTA. March 3, 2017

REQUIREMENTS OF PLASMA COLLECTION FOR PDMPs IPFA, YOGYAKARTA. March 3, 2017 REQUIREMENTS OF PLASMA COLLECTION FOR PDMPs IPFA, YOGYAKARTA March 3, 2017 OVERVIEW Recovered plasma requirements: EU fractionator point of view Collection of plasma Quality and audit requirements Safety

More information

General News. Product Notes. Instrument Notice HELENA SALES FORCE TO: FROM: SUBJECT: HELENA POINT OF CARE ROUND-UP/US DOMESTIC DATE: 9/1/2009

General News. Product Notes. Instrument Notice HELENA SALES FORCE TO: FROM: SUBJECT: HELENA POINT OF CARE ROUND-UP/US DOMESTIC DATE: 9/1/2009 TO: FROM: SUBJECT: HELENA SALES FORCE DATE: 9/1/2009 General News HELENA POINT OF CARE ROUND-UP/US DOMESTIC We have concluded a very large meeting with the AACC in Chicago. The leads have been processed

More information

The World Health Assembly Resolution on availability, safety and quality of blood products (WHA 63.12) Adopted May 2010

The World Health Assembly Resolution on availability, safety and quality of blood products (WHA 63.12) Adopted May 2010 The World Health Assembly Resolution on availability, safety and quality of blood products (WHA 63.12) Adopted May 2010 Dr Ana Padilla Blood Products & related Biologicals Essential Medicines and Pharmaceutical

More information

SPECIALIST IN BLOOD BANKING WORK EXPERIENCE DOCUMENTATION FORM (Routes 2, 3, & 4)

SPECIALIST IN BLOOD BANKING WORK EXPERIENCE DOCUMENTATION FORM (Routes 2, 3, & 4) PART I (TO BE COMPLETED BY APPLICANT) Applicant s Name Last Four Digits of Applicant s Social Security # Address Email Address Daytime Telephone Number PART II (MUST BE COMPLETED AND SIGNED BY THE IMMEDIATE

More information

Clinical Use of Plasma for Transfusion. Irma Szymanski, MD Professor of Pathology, Emerita University of Massachusetts Medical School

Clinical Use of Plasma for Transfusion. Irma Szymanski, MD Professor of Pathology, Emerita University of Massachusetts Medical School Clinical Use of Plasma for Transfusion Irma Szymanski, MD Professor of Pathology, Emerita University of Massachusetts Medical School PLASMA PRODUCTS FOR TRANSFUSION Fresh Frozen Plasma (FFP) Thawed Plasma

More information

STANDARDS FOR HEMATOPOIETIC PROGENITOR CELL COLLECTION, PROCESSING & TRANSPLANTATION

STANDARDS FOR HEMATOPOIETIC PROGENITOR CELL COLLECTION, PROCESSING & TRANSPLANTATION STANDARDS FOR HEMATOPOIETIC PROGENITOR CELL COLLECTION, PROCESSING & TRANSPLANTATION FROM THE JOINT ACCREDITATION COMMITTEE OF ISCT-EUROPE AND EBMT Second Edition - Europe June 2003 COPYRIGHT 2003 JOINT

More information

O NO YOU DIDN T! AN ABO-MISMATCHED PLATELET TRANSFUSION

O NO YOU DIDN T! AN ABO-MISMATCHED PLATELET TRANSFUSION O NO YOU DIDN T! AN ABO-MISMATCHED PLATELET TRANSFUSION L A U R I E W O L F M L S ( A S C P ) S B B U N I V E R S I T Y O F K A N S A S H O S P I T A L PATIENT OVERVIEW 11-4-2011 56 y/o male with a history

More information

2111: ALL Post-HCT. Add/ Remove/ Modify. Manual Section. Date. Description. Comprehensive Disease- Specific Manuals

2111: ALL Post-HCT. Add/ Remove/ Modify. Manual Section. Date. Description. Comprehensive Disease- Specific Manuals 2111: ALL Post-HCT The Acute Lymphoblastic Leukemia Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific post-hct data such as: planned treatments post-hct, the

More information

SPECIALIST IN BLOOD BANKING EXPERIENCE DOCUMENTATION FORM (Routes 2, 3 & 4)

SPECIALIST IN BLOOD BANKING EXPERIENCE DOCUMENTATION FORM (Routes 2, 3 & 4) PART I (To be completed by Applicant) SPECIALIST IN BLOOD BANKING EXPERIENCE DOCUMENTATION FORM (Routes 2, 3 & 4) Applicant s Name Last Four Digits of Applicant s Social Security # Address E-mail Address

More information

e-delphyn Blood Banking Information System

e-delphyn Blood Banking Information System e-delphyn Blood Banking Information System e-delphyn Blood Banking Information System offers a fully integrated blood banking information system with the following features: Blood Drive Administration

More information

5 TH WORLD VACCINES AND IMMUNOLOGY CONGRESS

5 TH WORLD VACCINES AND IMMUNOLOGY CONGRESS SPONSORSHIP & EXHIBITION 2019 Vaccines Congress 2019 Theme: Promulgate a vision in the field of vaccines and immunology 5 TH WORLD VACCINES AND IMMUNOLOGY CONGRESS June 10-11, 2019 Bangkok, Thailand http://vaccinescongress./

More information

NHS Blood and Transplant Appointment of Chief Executive. July NHS Blood and Transplant Appointment of Chief Executive

NHS Blood and Transplant Appointment of Chief Executive. July NHS Blood and Transplant Appointment of Chief Executive NHS Blood and Transplant Appointment of Chief Executive July 2018 Contents Welcome letter Introduction The role Core values, behaviours and expectations Diversity & Inclusion Organisational structure

More information

Contents BLOOD TRANSFUSION. Blood Transfusion Laboratory Index

Contents BLOOD TRANSFUSION. Blood Transfusion Laboratory Index BLOOD TRANSFUSION Contents INDEX: TEST REPERTOIRE - BLOOD TRANSFUSION... 53 including TRANSFUSION LABORATORY REQUEST OPTIONS, COMPONENT ISSUE and PRODUCT ISSUE USING THIS MANUAL... 54 CONTACT DETAILS OF

More information

Hospital Experience. Mike Herbert - Transfusion Laboratory Manager New Cross Hospital Wolverhampton

Hospital Experience. Mike Herbert - Transfusion Laboratory Manager New Cross Hospital Wolverhampton Hospital Experience Mike Herbert - Transfusion Laboratory Manager New Cross Hospital Wolverhampton Blood Stocks Management Scheme 2016 Annual Road Show 8th June 2016 Birmingham Ten Top Tips Understand

More information

10/17/ /17/2017

10/17/ /17/2017 Apheresis Objectives: Explain the concept of cell centrifugation Explain the concept of extracorporeal volume Name 2 methods of venous access for apheresis 1 What is Apheresis? Elements: Whole blood removal

More information

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency

More information

Short Title: CCI Biobank

Short Title: CCI Biobank Patient Label Stamp or letterhead of the department Patient Information Donation, Storage and Use of Biological Materials and Collection, Processing and Use of Data of the CCI Biobank, Medical Center -

More information

Platelet Transfusion Therapy

Platelet Transfusion Therapy REVIEW ARTICLE Platelet Transfusion Therapy *S Karim 1, E Hoque 2, MM Hoque 3, MMR Siddiqui 4 1 Dr. Shanaz Karim, Assistent Professor of Transfusion Medicine, Dhaka Medical College Hospital 2 Dr. Ehteshamul

More information